A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 604-605

  Ermilov, Marina ^a,d   Gelfin, Evgenia ^a,d   Levin, Raz ^a,d   Lichtenberg, Pesach ^a,d   Hashimoto, Kenji ^b   Javitt, Daniel C ^c   Heresco Levy, Uriel ^a,d  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c CHIBA UNIVERSITY   (Japan)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO SERINE; OLANZAPINE;

ABSENCE OF SIDE EFFECTS; ADULT; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LETTER; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT REFUSAL;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SCHIZOPHRENIA; SERINE; TIME FACTORS;

EID: 84886246956     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.09.018     Document Type: Letter

References (10)

1. Duggan L., Fenton M., Rathbone J., Dardennes R., El-Dosoky A., Indran S. Olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2005, 18:CD001359.
2. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
3. Hashimoto K., Fujita Y., Horio M., Kunitachi S., Iyo M., Ferraris D., Tsukamoto T. Co-administration of d-amino acid oxidase inhibitor potentiates the efficacy of d-serine on prepulse inhibition deficits after administration of dizocilpine. Biol. Psychiatry 2009, 65:1103-1106.
4. Heresco-Levy U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin. Emerg. Drugs 2005, 10:827-844.
5. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005, 57:577-585.
6. Javitt D.C., Zukin S.R., Heresco-Levy U., Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr. Bull. 2012, 38:958-966.
7. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
8. Kantrowitz J.T., Malhotra A.K., Cornblatt B., Silipo G., Balla A., Suckow R.F., D'Souza C., Saksa J., Woods S.W., Javitt D.C. High dose d-serine in the treatment of schizophrenia. Schizophr. Res. 2010, 121:125-130.
9. Meltzer H.Y., Bobo W.V., Roy A., Jayathilake K., Chen Y., Ertugrul A., Anil Yaǧcioǧlu A.E., Small J.G. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2008, 69:274-285.
10. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. d-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 1998, 44:1081-1089.